Showing results (891-900 of 926) with videos related to

Sort By:
Pageof 93
Nature|February 15, 2011
Crystal structure of a potassium ion transporter, TrkHYu Cao, Xiangshu Jin, Hua Huang, et al.
Vaccine|December 14, 2011
Safety, tolerability, and immunogenicity after 1 and 2 doses of zoster vaccine in healthy adults ≥60 years of ageJoost N Vermeulen, Joep M A Lange, Stephen K Tyring, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 21, 2022
AZD7442 (Tixagevimab/Cilgavimab) for Post-Exposure Prophylaxis of Symptomatic Coronavirus Disease 2019Myron J Levin, Andrew Ustianowski, Steven Thomas, et al.
Memorias Do Instituto Oswaldo Cruz|May 26, 2016
Serological based monitoring of a cohort of patients with chronic Chagas disease treated with benznidazole in a highly endemic area of northern ArgentinaLeticia L Niborski, Vanina Grippo, Sonia O Lafón, et al.
The Pediatric Infectious Disease Journal|May 7, 2005
GB virus C infection in children with perinatal human immunodeficiency virus infectionSusan Schuval, Jane C Lindsey, Jack T Stapleton, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 26, 2012
Persistence of the efficacy of zoster vaccine in the shingles prevention study and the short-term persistence substudyK E Schmader, M N Oxman, M J Levin, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|February 16, 2013
Varicella zoster virus-specific immune responses to a herpes zoster vaccine in elderly recipients with major depression and the impact of antidepressant medicationsMichael R Irwin, Myron J Levin, Mark L Laudenslager, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 15, 2010
Chemical generation of bispecific antibodiesVenkata R Doppalapudi, Jie Huang, Dingguo Liu, et al.
The Journal of Infectious Diseases|March 13, 2018
Immune Responses to a Recombinant Glycoprotein E Herpes Zoster Vaccine in Adults Aged 50 Years or OlderAnthony L Cunningham, Thomas C Heineman, Himal Lal, et al.
Clinical Drug Investigation|January 16, 2026
Safety and Pharmacokinetics of Repeat Dosing of Long-Acting SARS-CoV-2 Antibodies Tixagevimab/Cilgavimab (AZD7442): Results from the PROVENT Sub-studyAndrew Ustianowski, Myron J Levin, Stephane De Wit, et al.
Pageof 93